Lu Li, Zhou Jian-zhong, Wang Li, Zhang Tie-xu
The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chin J Integr Med. 2009 Aug;15(4):266-71. doi: 10.1007/s11655-009-0266-x. Epub 2009 Aug 18.
To investigate the impacts of Xuezhikang (XZK) or pravastatin combined with antihypertensive drugs on circulating endothelial progenitor cells (CEPCs) in essential hypertensive (EH) patients.
Eighty-eight EH patients were enrolled into the study and randomly assigned to the antihypertensive drug treatment group (ATH group, 29 cases), the pravastatin treatment group (PRA group, 29 cases) and the Xuezhikang treatment group (XZK group, 30 cases). Patients in the 3 groups were treated with routine antihypertensive drugs. In addition, pravastatin and Xuezhikang were given to the patients in the PRA group and XZK group, respectively. After an eight-week treatment, CEPCs were counted using a laser scanning confocal microscope, and their proliferation function was evaluated by the MTT colorimetric assay and the adherent cell number was counted to estimate the adhesion function.
After the treatment, CEPCs in the PRA group (116.60+/-5.70) and XZK group (114.40+/-6.55) was significantly higher than that in the ATH group (88.00+/-6.32, P<0.01). CEPCs proliferation capability and the adhesion function in the PRA group (0.406+/-0.016, 33.60+/-4.26) and XZK group (0.415+/-0.018, 34.30+/-3.77) were obviously superior to those in the ATH group (0.333+/-0.021, P<0.01; 23.30+/-3.19, P<0.01). No significant difference was found between the pravastatin group and the XZK group.
Combined use of XZK or pravastatin with the anti-hypertensive therapy could increase the CEPCs number and improve their function in EH patients with the blood pressure controlled by antihypertensive drugs, leading to benefits independent of pressure-lowering effects.
探讨血脂康（XZK）或普伐他汀联合降压药物对原发性高血压（EH）患者循环内皮祖细胞（CEPCs）的影响。
88例EH患者纳入研究，随机分为降压药物治疗组（ATH组，29例）、普伐他汀治疗组（PRA组，29例）和血脂康治疗组（XZK组，30例）。3组患者均接受常规降压药物治疗。此外，PRA组和XZK组患者分别给予普伐他汀和血脂康。治疗8周后，用激光扫描共聚焦显微镜计数CEPCs，并通过MTT比色法评估其增殖功能，计数贴壁细胞数以评估黏附功能。
治疗后，PRA组（116.60±5.70）和XZK组（114.40±6.55）的CEPCs明显高于ATH组（88.00±6.32，P<0.01）。PRA组（0.406±0.016，33.60±4.26）和XZK组（0.415±0.018，34.30±3.77）的CEPCs增殖能力和黏附功能明显优于ATH组（0.333±0.021，P<0.01；23.30±3.19，P<0.01）。普伐他汀组和血脂康组之间无显著差异。
在降压药物控制血压的EH患者中，XZK或普伐他汀与降压治疗联合使用可增加CEPCs数量并改善其功能，带来独立于降压作用的益处。
